Glucagon-like Peptide 1 Market to Witness Significant Growth of USD $30.5 Billion with 8.4% CAGR by 2029

 Get 30% Off Market Intelligence Reports With Code ONLINE30 — Track Global Tariffs, Economic Shifts, and Sector Transformations

 

 What Is the Forecast Market Size and Growth Rate of the Glucagon-like Peptide 1 Market by Region?
 The glucagon-like peptide 1 market size has grown strongly in recent years. It will grow from $20.88 billion in 2024 to $22.06 billion in 2025 at a compound annual growth rate (CAGR) of 5.7%. The growth in the historic period can be attributed to rising prevalence of diabetes, focus on improved diabetes management, patient preference for injectable therapies, clinical efficacy and safety profiles, advancements in diabetes research.
 
 The glucagon-like peptide 1 market size is expected to see strong growth in the next few years. It will grow to $30.5 billion in 2029 at a compound annual growth rate (CAGR) of 8.4%. The growth in the forecast period can be attributed to emergence of oral glp-1 therapies, focus on personalized medicine, integration in diabetes treatment algorithms, patient-centric approaches in healthcare. Major trends in the forecast period include market expansion in emerging economies, regulatory approvals for new formulations, focus on personalized medicine, patient education and awareness programs, competitive landscape dynamics.
 
 Claim your free report sample now:
 https://www.thebusinessresearchcompany.com/sample.aspx?id=10830&type=smp
 
 What Are the Top Drivers and Growth Contributors in the Glucagon-like Peptide 1 Market?
 The rising prevalence of diabetes is expected to propel the global glucagon-like peptide 1 market going forward. Diabetes is a condition in which the blood sugar, or blood glucose, is too high. Glucagon-like peptide 1 is a medication used to treat conditions such as type 2 diabetes that may lead to weight loss and improved blood sugar. For instance, in January 2022, according to the National Library of Medicine, a US-based center of biomedical informatics and computational biology, it was estimated that global diabetes prevalence in 20–79-year-olds in 2021 was 10.5% (536.6 million people), and it is expected to increase to 12.2% (783.2 million) in 2045. Therefore, the rising prevalence of diabetes will drive glucagon-like peptide 1.
 
 What Segments Are Covered in the Glucagon-like Peptide 1 Market Report?
 The glucagon-like peptide 1market covered in this report is segmented — 
 
 1) By Product: Trulicity, Ozempic, Victoza, Rybelsus, Other Types
 2) By Route of Administration: Oral, Parenteral, Other Routes
 3) By End-Users: Hospitals, Specialty Clinics, Other End Users
 
 Subsegments:
 1) By Trulicity: Injection (pre-filled pen), Dosage forms (0.75 mg, 1.5 mg, etc.)
 2) By Ozempic: Injection (pre-filled pen), Dosage forms (0.5 mg, 1 mg, etc.)
 3) By Victoza: Injection (pre-filled pen), Dosage forms (1.2 mg, 1.8 mg, etc.)
 4) By Rybelsus: Oral tablet (3 mg, 7 mg, 14 mg)
 5) By Other Types: Experimental formulations, Combination products with other medications, Alternative delivery systems
 
 What Are the Key Trends Shaping the Glucagon-like Peptide 1 Market?
 Technological innovations are a key trend gaining popularity in the global glucagon-like peptide 1 market. Major companies operating in the glucagon-like peptide 1 market are launching new and innovative technologies to sustain their position in the market. For instance, in March 2024, Novo Nordisk A/S, a Denmark-based pharmaceutical company, launched Wegovy, the first and only once-weekly glucagon-like peptide 1 therapy for weight management. Wegovy completed the STEP Phase 3a clinical trial program and demonstrated a safe and well-tolerated profile across the program. This product is used by people who struggle with obesity to achieve and maintain weight loss.
 
 Who Are the Industry Leaders in the Glucagon-like Peptide 1 Market?
 Major companies operating in the glucagon-like peptide 1 market include Novo Nordisk AS, Sanofi SA, Eli Lilly and Co, AstraZeneca plc, Pfizer Inc, Boehringer Ingelheim International GmbH, F Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Baxter, Hikma Pharmaceuticals plc, Zealand Pharma A/S, Intarcia Therapeutics Inc., GlaxoSmithKline plc, Jiangsu Hansoh Pharmaceutical Group Co Ltd, Shanghai Benemae Pharmaceutical Corporation, Adocia, Biocon, Hanmi Pharmaceutical Co Ltd, Ligand Pharmaceuticals Incorporated, Advinus Therapeutics Ltd, Mitsubishi Tanabe Pharma Corporation, Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd, Union Chimique Belge, Amylin Pharmaceuticals LLC, Academic Pharmaceuticals Inc, ConjuChem Biotechnologies, MannKind Corporation:, Provention Bio Inc, Regeneron Pharmaceuticals 
 
 Get the full glucagon-like peptide 1 market report here:
 https://www.thebusinessresearchcompany.com/report/glucagon-like-peptide-1-global-market-report
 
 Which Region Is Projected to Account for the Largest Share of the Glucagon-like Peptide 1 Market?
 North America was the largest region in the glucagon-like peptide 1 market in 2024. The regions covered in the glucagon-like peptide 1 market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
 
 Contact Us:
 The Business Research Company: https://thebusinessresearchcompany.com/ 
 
 Americas +1 310–496–7795
 Asia +44 7882 955267 & +91 8897263534
 Europe +44 7882 955267 
 Email: info@tbrc.info 
 
 Follow Us On:
 LinkedIn: https://in.linkedin.com/company/the-business-research-company